ParkinsonCanadaV1, PascalFrancis, Corpus, bibRecord, 000074

Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia

Identifieur interne : 000074 ( PascalFrancis/Corpus ); précédent : 000073; suivant : 000075

Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia

Auteurs : Christopher Kobylecki ; Alan R. Crossman ; Paula Ravenscroft

Source :

Experimental neurology : (Print) [ 0014-4886 ] ; 2013.

RBID : Pascal:13-0283965

Descripteurs français

Pascal (Inist)
- Maladie de Parkinson, Dyskinésie, Pathologie du système nerveux, Epissage, Récepteur AMPA, Sousunité, Modèle animal, Lévodopa, Calcium, Glutamate.

English descriptors

KwdEn :
- AMPA receptor, Animal model, Calcium, Dyskinesia, Glutamate, Levodopa, Nervous system diseases, Parkinson disease, Splicing, Subunit.

Abstract

Abnormal corticostriatal plasticity is a key mechanism of L-DOPA-induced dyskinesia (LID) in Parkinson's disease (PD). Antagonists at glutamatergic α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, such as IEM 1460, reduce induction and expression of dyskinesia in rat and non-human primate models of PD. AMPA receptor function is regulated by post-transcriptional splicing of subunit mRNA to produce flip and flop isoforms, which may therefore influence corticostriatal plasticity. The aim of this work was to evaluate alterations in alternative splicing of striatal AMPA receptor subunits in the unilateral 6-hydroxydopamine (6-OHDA)-lesioned rat model of LID and PD. Male Sprague-Dawley rats received 12.5 μg 6-OHDA injections into the right medial forebrain bundle. In experiment 1, to assess acute dyskinesia, rats received L-DOPA/ benserazide (6/15 mg/kg, i.p.) or vehicle for 21 days. In experiment 2, to assess dyskinesia priming, rats received vehicle, L-DOPA + vehicle or L-DOPA + IEM 1460 (3 mg/kg, i.p.) for 21 days. Animals were humanely killed 1 h following final treatment in experiment 1, and 48 h following final treatment in experiment 2. Coronal sections of rostral striatum were processed for in situ hybridisation histochemistry, using oligonucleotide probes specific for the GluR1 and GluR2 subunits and their flip and flop isoforms. L-DOPA treatment increased GluR2-flip mRNA expression in the lesioned striatum of both groups; this was blocked by the Ca²⁺-permeable AMPA receptor antagonist IEM 1460. GluR1-flip expression was increased after 48 h drug washout but not in acute LID. There were no changes in expression of flop isoforms. Alternative splicing of AMPAR subunits contributes to abnormal striatal plasticity in the induction and expression of LID. Increases in GluR2-flip expression depend on activation of Ca²⁺-permeable AMPA receptors, which are a potential target of anti-dyskinetic therapies.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0014-4886`
A02	`01`			`@0 EXNEAC`
A03		`1`		`@0 Exp. neurol. : (Print)`
A05				`@2 247`
A08	`01`	`1`	`ENG`	`@1 Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia`
A11	`01`	`1`		`@1 KOBYLECKI (Christopher)`
A11	`02`	`1`		`@1 CROSSMAN (Alan R.)`
A11	`03`	`1`		`@1 RAVENSCROFT (Paula)`
A14	`01`			`@1 Institute of Brain, Behaviour and Mental Health, University of Manchester @3 GBR @Z 1 aut.`
A14	`02`			`@1 Faculty of Life Sciences, University of Manchester @3 GBR @Z 1 aut. @Z 2 aut. @Z 3 aut.`
A14	`03`			`@1 Department of Neurology, Greater Manchester Neurosciences Centre @2 Salford @3 GBR @Z 1 aut.`
A14	`04`			`@1 Toronto Western Research Institute, University Health Network @2 Toronto @3 CAN @Z 3 aut.`
A20				`@1 476-484`
A21				`@1 2013`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 9181 @5 354000501505990570`
A44				`@0 0000 @1 © 2013 INIST-CNRS. All rights reserved.`
A45				`@0 1 p.1/4`
A47	`01`	`1`		`@0 13-0283965`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Experimental neurology : (Print)`
A66	`01`			`@0 NLD`
C01	`01`		`ENG`	@0 Abnormal corticostriatal plasticity is a key mechanism of L-DOPA-induced dyskinesia (LID) in Parkinson's disease (PD). Antagonists at glutamatergic α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, such as IEM 1460, reduce induction and expression of dyskinesia in rat and non-human primate models of PD. AMPA receptor function is regulated by post-transcriptional splicing of subunit mRNA to produce flip and flop isoforms, which may therefore influence corticostriatal plasticity. The aim of this work was to evaluate alterations in alternative splicing of striatal AMPA receptor subunits in the unilateral 6-hydroxydopamine (6-OHDA)-lesioned rat model of LID and PD. Male Sprague-Dawley rats received 12.5 μg 6-OHDA injections into the right medial forebrain bundle. In experiment 1, to assess acute dyskinesia, rats received L-DOPA/ benserazide (6/15 mg/kg, i.p.) or vehicle for 21 days. In experiment 2, to assess dyskinesia priming, rats received vehicle, L-DOPA + vehicle or L-DOPA + IEM 1460 (3 mg/kg, i.p.) for 21 days. Animals were humanely killed 1 h following final treatment in experiment 1, and 48 h following final treatment in experiment 2. Coronal sections of rostral striatum were processed for in situ hybridisation histochemistry, using oligonucleotide probes specific for the GluR1 and GluR2 subunits and their flip and flop isoforms. L-DOPA treatment increased GluR2-flip mRNA expression in the lesioned striatum of both groups; this was blocked by the Ca²⁺-permeable AMPA receptor antagonist IEM 1460. GluR1-flip expression was increased after 48 h drug washout but not in acute LID. There were no changes in expression of flop isoforms. Alternative splicing of AMPAR subunits contributes to abnormal striatal plasticity in the induction and expression of LID. Increases in GluR2-flip expression depend on activation of Ca²⁺-permeable AMPA receptors, which are a potential target of anti-dyskinetic therapies.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B17G`
C03	`01`	`X`	`FRE`	`@0 Maladie de Parkinson @2 NM @5 01`
C03	`01`	`X`	`ENG`	`@0 Parkinson disease @2 NM @5 01`
C03	`01`	`X`	`SPA`	`@0 Parkinson enfermedad @2 NM @5 01`
C03	`02`	`X`	`FRE`	`@0 Dyskinésie @5 02`
C03	`02`	`X`	`ENG`	`@0 Dyskinesia @5 02`
C03	`02`	`X`	`SPA`	`@0 Disquinesia @5 02`
C03	`03`	`X`	`FRE`	`@0 Pathologie du système nerveux @5 03`
C03	`03`	`X`	`ENG`	`@0 Nervous system diseases @5 03`
C03	`03`	`X`	`SPA`	`@0 Sistema nervioso patología @5 03`
C03	`04`	`X`	`FRE`	`@0 Epissage @5 09`
C03	`04`	`X`	`ENG`	`@0 Splicing @5 09`
C03	`04`	`X`	`SPA`	`@0 Empalme @5 09`
C03	`05`	`X`	`FRE`	`@0 Récepteur AMPA @5 10`
C03	`05`	`X`	`ENG`	`@0 AMPA receptor @5 10`
C03	`05`	`X`	`SPA`	`@0 Receptor AMPA @5 10`
C03	`06`	`X`	`FRE`	`@0 Sousunité @5 11`
C03	`06`	`X`	`ENG`	`@0 Subunit @5 11`
C03	`06`	`X`	`SPA`	`@0 Subunitad @5 11`
C03	`07`	`X`	`FRE`	`@0 Modèle animal @5 12`
C03	`07`	`X`	`ENG`	`@0 Animal model @5 12`
C03	`07`	`X`	`SPA`	`@0 Modelo animal @5 12`
C03	`08`	`X`	`FRE`	`@0 Lévodopa @2 NK @2 FR @5 13`
C03	`08`	`X`	`ENG`	`@0 Levodopa @2 NK @2 FR @5 13`
C03	`08`	`X`	`SPA`	`@0 Levodopa @2 NK @2 FR @5 13`
C03	`09`	`X`	`FRE`	`@0 Calcium @2 NC @2 FR @5 14`
C03	`09`	`X`	`ENG`	`@0 Calcium @2 NC @2 FR @5 14`
C03	`09`	`X`	`SPA`	`@0 Calcio @2 NC @2 FR @5 14`
C03	`10`	`X`	`FRE`	`@0 Glutamate @2 NK @2 FX @5 15`
C03	`10`	`X`	`ENG`	`@0 Glutamate @2 NK @2 FX @5 15`
C03	`10`	`X`	`SPA`	`@0 Glutamato @2 NK @2 FX @5 15`
C07	`01`	`X`	`FRE`	`@0 Récepteur glutamate @5 37`
C07	`01`	`X`	`ENG`	`@0 Glutamate receptor @5 37`
C07	`01`	`X`	`SPA`	`@0 Receptor glutámato @5 37`
C07	`02`	`X`	`FRE`	`@0 Pathologie de l'encéphale @5 38`
C07	`02`	`X`	`ENG`	`@0 Cerebral disorder @5 38`
C07	`02`	`X`	`SPA`	`@0 Encéfalo patología @5 38`
C07	`03`	`X`	`FRE`	`@0 Syndrome extrapyramidal @5 39`
C07	`03`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 39`
C07	`03`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 39`
C07	`04`	`X`	`FRE`	`@0 Maladie dégénérative @5 40`
C07	`04`	`X`	`ENG`	`@0 Degenerative disease @5 40`
C07	`04`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 40`
C07	`05`	`X`	`FRE`	`@0 Pathologie du système nerveux central @5 41`
C07	`05`	`X`	`ENG`	`@0 Central nervous system disease @5 41`
C07	`05`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 41`
C07	`06`	`X`	`FRE`	`@0 Mouvement involontaire @5 43`
C07	`06`	`X`	`ENG`	`@0 Involuntary movement @5 43`
C07	`06`	`X`	`SPA`	`@0 Movimiento involuntario @5 43`
C07	`07`	`X`	`FRE`	`@0 Trouble neurologique @5 44`
C07	`07`	`X`	`ENG`	`@0 Neurological disorder @5 44`
C07	`07`	`X`	`SPA`	`@0 Trastorno neurológico @5 44`
C07	`08`	`X`	`FRE`	`@0 Aminoacide excitateur @5 45`
C07	`08`	`X`	`ENG`	`@0 Excitatory aminoacid @5 45`
C07	`08`	`X`	`SPA`	`@0 Aminoácido excitador @5 45`
C07	`09`	`X`	`FRE`	`@0 Neurotransmetteur @5 46`
C07	`09`	`X`	`ENG`	`@0 Neurotransmitter @5 46`
C07	`09`	`X`	`SPA`	`@0 Neurotransmisor @5 46`
N21				`@1 266`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 13-0283965 INIST
ET :	Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia
AU :	KOBYLECKI (Christopher); CROSSMAN (Alan R.); RAVENSCROFT (Paula)
AF :	Institute of Brain, Behaviour and Mental Health, University of Manchester/Royaume-Uni (1 aut.); Faculty of Life Sciences, University of Manchester/Royaume-Uni (1 aut., 2 aut., 3 aut.); Department of Neurology, Greater Manchester Neurosciences Centre/Salford/Royaume-Uni (1 aut.); Toronto Western Research Institute, University Health Network/Toronto/Canada (3 aut.)
DT :	Publication en série; Niveau analytique
SO :	Experimental neurology : (Print); ISSN 0014-4886; Coden EXNEAC; Pays-Bas; Da. 2013; Vol. 247; Pp. 476-484; Bibl. 1 p.1/4
LA :	Anglais
EA :	Abnormal corticostriatal plasticity is a key mechanism of L-DOPA-induced dyskinesia (LID) in Parkinson's disease (PD). Antagonists at glutamatergic α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors, such as IEM 1460, reduce induction and expression of dyskinesia in rat and non-human primate models of PD. AMPA receptor function is regulated by post-transcriptional splicing of subunit mRNA to produce flip and flop isoforms, which may therefore influence corticostriatal plasticity. The aim of this work was to evaluate alterations in alternative splicing of striatal AMPA receptor subunits in the unilateral 6-hydroxydopamine (6-OHDA)-lesioned rat model of LID and PD. Male Sprague-Dawley rats received 12.5 μg 6-OHDA injections into the right medial forebrain bundle. In experiment 1, to assess acute dyskinesia, rats received L-DOPA/ benserazide (6/15 mg/kg, i.p.) or vehicle for 21 days. In experiment 2, to assess dyskinesia priming, rats received vehicle, L-DOPA + vehicle or L-DOPA + IEM 1460 (3 mg/kg, i.p.) for 21 days. Animals were humanely killed 1 h following final treatment in experiment 1, and 48 h following final treatment in experiment 2. Coronal sections of rostral striatum were processed for in situ hybridisation histochemistry, using oligonucleotide probes specific for the GluR1 and GluR2 subunits and their flip and flop isoforms. L-DOPA treatment increased GluR2-flip mRNA expression in the lesioned striatum of both groups; this was blocked by the Ca²⁺-permeable AMPA receptor antagonist IEM 1460. GluR1-flip expression was increased after 48 h drug washout but not in acute LID. There were no changes in expression of flop isoforms. Alternative splicing of AMPAR subunits contributes to abnormal striatal plasticity in the induction and expression of LID. Increases in GluR2-flip expression depend on activation of Ca²⁺-permeable AMPA receptors, which are a potential target of anti-dyskinetic therapies.
CC :	002B17; 002B17G
FD :	Maladie de Parkinson; Dyskinésie; Pathologie du système nerveux; Epissage; Récepteur AMPA; Sousunité; Modèle animal; Lévodopa; Calcium; Glutamate
FG :	Récepteur glutamate; Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du système nerveux central; Mouvement involontaire; Trouble neurologique; Aminoacide excitateur; Neurotransmetteur
ED :	Parkinson disease; Dyskinesia; Nervous system diseases; Splicing; AMPA receptor; Subunit; Animal model; Levodopa; Calcium; Glutamate
EG :	Glutamate receptor; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease; Involuntary movement; Neurological disorder; Excitatory aminoacid; Neurotransmitter
SD :	Parkinson enfermedad; Disquinesia; Sistema nervioso patología; Empalme; Receptor AMPA; Subunitad; Modelo animal; Levodopa; Calcio; Glutamato
LO :	INIST-9181.354000501505990570
ID :	13-0283965

Links to Exploration step

Pascal:13-0283965

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia</title>
<author><name sortKey="Kobylecki, Christopher" sort="Kobylecki, Christopher" uniqKey="Kobylecki C" first="Christopher" last="Kobylecki">Christopher Kobylecki</name>
<affiliation><inist:fA14 i1="01"><s1>Institute of Brain, Behaviour and Mental Health, University of Manchester</s1>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Faculty of Life Sciences, University of Manchester</s1>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Department of Neurology, Greater Manchester Neurosciences Centre</s1>
<s2>Salford</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Crossman, Alan R" sort="Crossman, Alan R" uniqKey="Crossman A" first="Alan R." last="Crossman">Alan R. Crossman</name>
<affiliation><inist:fA14 i1="02"><s1>Faculty of Life Sciences, University of Manchester</s1>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ravenscroft, Paula" sort="Ravenscroft, Paula" uniqKey="Ravenscroft P" first="Paula" last="Ravenscroft">Paula Ravenscroft</name>
<affiliation><inist:fA14 i1="02"><s1>Faculty of Life Sciences, University of Manchester</s1>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>Toronto Western Research Institute, University Health Network</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">13-0283965</idno>
<date when="2013">2013</date>
<idno type="stanalyst">PASCAL 13-0283965 INIST</idno>
<idno type="RBID">Pascal:13-0283965</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000074</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia</title>
<author><name sortKey="Kobylecki, Christopher" sort="Kobylecki, Christopher" uniqKey="Kobylecki C" first="Christopher" last="Kobylecki">Christopher Kobylecki</name>
<affiliation><inist:fA14 i1="01"><s1>Institute of Brain, Behaviour and Mental Health, University of Manchester</s1>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Faculty of Life Sciences, University of Manchester</s1>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Department of Neurology, Greater Manchester Neurosciences Centre</s1>
<s2>Salford</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Crossman, Alan R" sort="Crossman, Alan R" uniqKey="Crossman A" first="Alan R." last="Crossman">Alan R. Crossman</name>
<affiliation><inist:fA14 i1="02"><s1>Faculty of Life Sciences, University of Manchester</s1>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ravenscroft, Paula" sort="Ravenscroft, Paula" uniqKey="Ravenscroft P" first="Paula" last="Ravenscroft">Paula Ravenscroft</name>
<affiliation><inist:fA14 i1="02"><s1>Faculty of Life Sciences, University of Manchester</s1>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>Toronto Western Research Institute, University Health Network</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Experimental neurology : (Print)</title>
<title level="j" type="abbreviated">Exp. neurol. : (Print)</title>
<idno type="ISSN">0014-4886</idno>
<imprint><date when="2013">2013</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Experimental neurology : (Print)</title>
<title level="j" type="abbreviated">Exp. neurol. : (Print)</title>
<idno type="ISSN">0014-4886</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>AMPA receptor</term>
<term>Animal model</term>
<term>Calcium</term>
<term>Dyskinesia</term>
<term>Glutamate</term>
<term>Levodopa</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Splicing</term>
<term>Subunit</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Maladie de Parkinson</term>
<term>Dyskinésie</term>
<term>Pathologie du   système nerveux</term>
<term>Epissage</term>
<term>Récepteur AMPA</term>
<term>Sousunité</term>
<term>Modèle animal</term>
<term>Lévodopa</term>
<term>Calcium</term>
<term>Glutamate</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Abnormal corticostriatal plasticity is a key mechanism of L-DOPA-induced dyskinesia (LID) in Parkinson's disease (PD). Antagonists at glutamatergic α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, such as IEM 1460, reduce induction and expression of dyskinesia in rat and non-human primate models of PD. AMPA receptor function is regulated by post-transcriptional splicing of subunit mRNA to produce flip and flop isoforms, which may therefore influence corticostriatal plasticity. The aim of this work was to evaluate alterations in alternative splicing of striatal AMPA receptor subunits in the unilateral 6-hydroxydopamine (6-OHDA)-lesioned rat model of LID and PD. Male Sprague-Dawley rats received 12.5 μg 6-OHDA injections into the right medial forebrain bundle. In experiment 1, to assess acute dyskinesia, rats received L-DOPA/ benserazide (6/15 mg/kg, i.p.) or vehicle for 21 days. In experiment 2, to assess dyskinesia priming, rats received vehicle, L-DOPA + vehicle or L-DOPA + IEM 1460 (3 mg/kg, i.p.) for 21 days. Animals were humanely killed 1 h following final treatment in experiment 1, and 48 h following final treatment in experiment 2. Coronal sections of rostral striatum were processed for in situ hybridisation histochemistry, using oligonucleotide probes specific for the GluR1 and GluR2 subunits and their flip and flop isoforms. L-DOPA treatment increased GluR2-flip mRNA expression in the lesioned striatum of both groups; this was blocked by the Ca<sup>2+</sup>
-permeable AMPA receptor antagonist IEM 1460. GluR1-flip expression was increased after 48 h drug washout but not in acute LID. There were no changes in expression of flop isoforms. Alternative splicing of AMPAR subunits contributes to abnormal striatal plasticity in the induction and expression of LID. Increases in GluR2-flip expression depend on activation of Ca<sup>2+</sup>
-permeable AMPA receptors, which are a potential target of anti-dyskinetic therapies.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0014-4886</s0>
</fA01>
<fA02 i1="01"><s0>EXNEAC</s0>
</fA02>
<fA03 i2="1"><s0>Exp. neurol. : (Print)</s0>
</fA03>
<fA05><s2>247</s2>
</fA05>
<fA08 i1="01" i2="1" l="ENG"><s1>Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>KOBYLECKI (Christopher)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>CROSSMAN (Alan R.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>RAVENSCROFT (Paula)</s1>
</fA11>
<fA14 i1="01"><s1>Institute of Brain, Behaviour and Mental Health, University of Manchester</s1>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Faculty of Life Sciences, University of Manchester</s1>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Department of Neurology, Greater Manchester Neurosciences Centre</s1>
<s2>Salford</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Toronto Western Research Institute, University Health Network</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA20><s1>476-484</s1>
</fA20>
<fA21><s1>2013</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>9181</s2>
<s5>354000501505990570</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2013 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>1 p.1/4</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>13-0283965</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Experimental neurology : (Print)</s0>
</fA64>
<fA66 i1="01"><s0>NLD</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Abnormal corticostriatal plasticity is a key mechanism of L-DOPA-induced dyskinesia (LID) in Parkinson's disease (PD). Antagonists at glutamatergic α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, such as IEM 1460, reduce induction and expression of dyskinesia in rat and non-human primate models of PD. AMPA receptor function is regulated by post-transcriptional splicing of subunit mRNA to produce flip and flop isoforms, which may therefore influence corticostriatal plasticity. The aim of this work was to evaluate alterations in alternative splicing of striatal AMPA receptor subunits in the unilateral 6-hydroxydopamine (6-OHDA)-lesioned rat model of LID and PD. Male Sprague-Dawley rats received 12.5 μg 6-OHDA injections into the right medial forebrain bundle. In experiment 1, to assess acute dyskinesia, rats received L-DOPA/ benserazide (6/15 mg/kg, i.p.) or vehicle for 21 days. In experiment 2, to assess dyskinesia priming, rats received vehicle, L-DOPA + vehicle or L-DOPA + IEM 1460 (3 mg/kg, i.p.) for 21 days. Animals were humanely killed 1 h following final treatment in experiment 1, and 48 h following final treatment in experiment 2. Coronal sections of rostral striatum were processed for in situ hybridisation histochemistry, using oligonucleotide probes specific for the GluR1 and GluR2 subunits and their flip and flop isoforms. L-DOPA treatment increased GluR2-flip mRNA expression in the lesioned striatum of both groups; this was blocked by the Ca<sup>2+</sup>
-permeable AMPA receptor antagonist IEM 1460. GluR1-flip expression was increased after 48 h drug washout but not in acute LID. There were no changes in expression of flop isoforms. Alternative splicing of AMPAR subunits contributes to abnormal striatal plasticity in the induction and expression of LID. Increases in GluR2-flip expression depend on activation of Ca<sup>2+</sup>
-permeable AMPA receptors, which are a potential target of anti-dyskinetic therapies.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Maladie de Parkinson</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Dyskinésie</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Dyskinesia</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Disquinesia</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Epissage</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Splicing</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Empalme</s0>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Récepteur AMPA</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>AMPA receptor</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Receptor AMPA</s0>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Sousunité</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Subunit</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Subunitad</s0>
<s5>11</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Modèle animal</s0>
<s5>12</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Animal model</s0>
<s5>12</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Modelo animal</s0>
<s5>12</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Lévodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>13</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Levodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>13</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Levodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>13</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Calcium</s0>
<s2>NC</s2>
<s2>FR</s2>
<s5>14</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Calcium</s0>
<s2>NC</s2>
<s2>FR</s2>
<s5>14</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Calcio</s0>
<s2>NC</s2>
<s2>FR</s2>
<s5>14</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Glutamate</s0>
<s2>NK</s2>
<s2>FX</s2>
<s5>15</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Glutamate</s0>
<s2>NK</s2>
<s2>FX</s2>
<s5>15</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Glutamato</s0>
<s2>NK</s2>
<s2>FX</s2>
<s5>15</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Récepteur glutamate</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Glutamate receptor</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Receptor glutámato</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Pathologie du   système nerveux central</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Mouvement involontaire</s0>
<s5>43</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Involuntary movement</s0>
<s5>43</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Movimiento involuntario</s0>
<s5>43</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Trouble neurologique</s0>
<s5>44</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Neurological disorder</s0>
<s5>44</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Trastorno neurológico</s0>
<s5>44</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Aminoacide excitateur</s0>
<s5>45</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Excitatory aminoacid</s0>
<s5>45</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Aminoácido excitador</s0>
<s5>45</s5>
</fC07>
<fC07 i1="09" i2="X" l="FRE"><s0>Neurotransmetteur</s0>
<s5>46</s5>
</fC07>
<fC07 i1="09" i2="X" l="ENG"><s0>Neurotransmitter</s0>
<s5>46</s5>
</fC07>
<fC07 i1="09" i2="X" l="SPA"><s0>Neurotransmisor</s0>
<s5>46</s5>
</fC07>
<fN21><s1>266</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 13-0283965 INIST</NO>
<ET>Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia</ET>
<AU>KOBYLECKI (Christopher); CROSSMAN (Alan R.); RAVENSCROFT (Paula)</AU>
<AF>Institute of Brain, Behaviour and Mental Health, University of Manchester/Royaume-Uni (1 aut.); Faculty of Life Sciences, University of Manchester/Royaume-Uni (1 aut., 2 aut., 3 aut.); Department of Neurology, Greater Manchester Neurosciences Centre/Salford/Royaume-Uni (1 aut.); Toronto Western Research Institute, University Health Network/Toronto/Canada (3 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Experimental neurology : (Print); ISSN 0014-4886; Coden EXNEAC; Pays-Bas; Da. 2013; Vol. 247; Pp. 476-484; Bibl. 1 p.1/4</SO>
<LA>Anglais</LA>
<EA>Abnormal corticostriatal plasticity is a key mechanism of L-DOPA-induced dyskinesia (LID) in Parkinson's disease (PD). Antagonists at glutamatergic α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors, such as IEM 1460, reduce induction and expression of dyskinesia in rat and non-human primate models of PD. AMPA receptor function is regulated by post-transcriptional splicing of subunit mRNA to produce flip and flop isoforms, which may therefore influence corticostriatal plasticity. The aim of this work was to evaluate alterations in alternative splicing of striatal AMPA receptor subunits in the unilateral 6-hydroxydopamine (6-OHDA)-lesioned rat model of LID and PD. Male Sprague-Dawley rats received 12.5 μg 6-OHDA injections into the right medial forebrain bundle. In experiment 1, to assess acute dyskinesia, rats received L-DOPA/ benserazide (6/15 mg/kg, i.p.) or vehicle for 21 days. In experiment 2, to assess dyskinesia priming, rats received vehicle, L-DOPA + vehicle or L-DOPA + IEM 1460 (3 mg/kg, i.p.) for 21 days. Animals were humanely killed 1 h following final treatment in experiment 1, and 48 h following final treatment in experiment 2. Coronal sections of rostral striatum were processed for in situ hybridisation histochemistry, using oligonucleotide probes specific for the GluR1 and GluR2 subunits and their flip and flop isoforms. L-DOPA treatment increased GluR2-flip mRNA expression in the lesioned striatum of both groups; this was blocked by the Ca<sup>2+</sup>
-permeable AMPA receptor antagonist IEM 1460. GluR1-flip expression was increased after 48 h drug washout but not in acute LID. There were no changes in expression of flop isoforms. Alternative splicing of AMPAR subunits contributes to abnormal striatal plasticity in the induction and expression of LID. Increases in GluR2-flip expression depend on activation of Ca<sup>2+</sup>
-permeable AMPA receptors, which are a potential target of anti-dyskinetic therapies.</EA>
<CC>002B17; 002B17G</CC>
<FD>Maladie de Parkinson; Dyskinésie; Pathologie du   système nerveux; Epissage; Récepteur AMPA; Sousunité; Modèle animal; Lévodopa; Calcium; Glutamate</FD>
<FG>Récepteur glutamate; Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du   système nerveux central; Mouvement involontaire; Trouble neurologique; Aminoacide excitateur; Neurotransmetteur</FG>
<ED>Parkinson disease; Dyskinesia; Nervous system diseases; Splicing; AMPA receptor; Subunit; Animal model; Levodopa; Calcium; Glutamate</ED>
<EG>Glutamate receptor; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease; Involuntary movement; Neurological disorder; Excitatory aminoacid; Neurotransmitter</EG>
<SD>Parkinson enfermedad; Disquinesia; Sistema nervioso patología; Empalme; Receptor AMPA; Subunitad; Modelo animal; Levodopa; Calcio; Glutamato</SD>
<LO>INIST-9181.354000501505990570</LO>
<ID>13-0283965</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000074 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000074 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:13-0283965
   |texte=   Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson au Canada (serveur d'exploration)

Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia

Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri